HKSE - Delayed Quote HKD

Giant Biogene Holding Co., Ltd. (2367.HK)

Compare
71.400
+0.150
+(0.21%)
At close: 4:08:14 PM GMT+8
Loading Chart for 2367.HK
  • Previous Close 71.250
  • Open 70.100
  • Bid 71.300 x --
  • Ask 71.500 x --
  • Day's Range 68.850 - 73.350
  • 52 Week Range 35.000 - 75.200
  • Volume 3,645,922
  • Avg. Volume 3,577,979
  • Market Cap (intraday) 73.009B
  • Beta (5Y Monthly) 0.79
  • PE Ratio (TTM) 32.31
  • EPS (TTM) 2.210
  • Earnings Date --
  • Forward Dividend & Yield 0.65 (0.91%)
  • Ex-Dividend Date Jun 17, 2025
  • 1y Target Est 79.74

Giant Biogene Holding Co., Ltd., an investment holding company, engages in the research, development, manufacture, and sale of bioactive material-based beauty and health products in the People's Republic of China. It also manufactures rare ginsenosides technology-based functional foods; and offers medical devices. The company offers its functional skincare products, medical dressings, and functional foods primarily under the Comfy, Collgene, Keyu, and SKIGIN brands. Giant Biogene Holding Co., Ltd. was founded in 2000 and is headquartered in Xi'an, the People's Republic of China.

www.xajuzi.com

1,758

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 2367.HK

View More

Performance Overview: 2367.HK

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

2367.HK
42.23%
HANG SENG INDEX (^HSI)
13.91%

1-Year Return

2367.HK
67.53%
HANG SENG INDEX (^HSI)
36.62%

3-Year Return

2367.HK
174.62%
HANG SENG INDEX (^HSI)
3.68%

5-Year Return

2367.HK
174.62%
HANG SENG INDEX (^HSI)
1.66%

Compare To: 2367.HK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 2367.HK

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    72.86B

  • Enterprise Value

    66.58B

  • Trailing P/E

    32.27

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    12.02

  • Price/Book (mrq)

    9.56

  • Enterprise Value/Revenue

    11.22

  • Enterprise Value/EBITDA

    25.27

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    37.23%

  • Return on Assets (ttm)

    21.89%

  • Return on Equity (ttm)

    35.88%

  • Revenue (ttm)

    5.54B

  • Net Income Avi to Common (ttm)

    2.06B

  • Diluted EPS (ttm)

    2.210

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.88B

  • Total Debt/Equity (mrq)

    0.09%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 2367.HK

View More

Company Insights: 2367.HK

Research Reports: 2367.HK

View More

People Also Watch